BioAge Labs (BIOA) Price to Sales (2025 - 2026)
BioAge Labs' (BIOA) quarterly Price to Sales came in at 457.77 in Q2 2026, up 645.73% year-over-year from 61.39 in Q2 2025, and up 63.45% quarter-over-quarter from 280.06 in Q1 2026.
Powered by 
Analysis
BioAge Labs (BIOA) Price to Sales (2025 - 2026) Analysis & Trends
BioAge Labs has disclosed Price to Sales across 2 years of filings, most recently posting 457.77 for Q2 2026.
- In Q2 2026, Price to Sales rose 645.73% year-over-year to 457.77; the TTM figure through Jun 2026 stood at 108.35 (up 182.7% YoY), while the FY2025 annual figure was 54.99, changed N/A from the prior year.
- Price to Sales came in at 457.77 for Q2 2026 at BioAge Labs, up from 280.06 in the prior quarter.
- In the past five years, Price to Sales ranged from a high of 457.77 in Q2 2026 to a low of 61.39 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | BioAge Labs | 439.00 Mn | 439.00 Mn | -14.23 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 457.77 |
| Mar 31, 2026 | 280.06 |
| Dec 31, 2025 | 160.70 |
| Sep 30, 2025 | 102.63 |
| Jun 30, 2025 | 61.39 |
| Mar 31, 2025 | 92.90 |